Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Watchlist Manager
Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Watchlist
Price: 46.16 USD 1.63%
Market Cap: 2.6B USD
Section:
 

Relative Value

The Relative Value of one SUPN stock under the Base Case scenario is hidden USD. Compared to the current market price of 46.16 USD, Supernus Pharmaceuticals Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SUPN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

3.9
P/S
P/S
Price to Sales
3.9
vs History
3
vs Industry
41
Median 3Y
2.8
Median 5Y
2.8
Industry
2.6
Forward
3.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
19
Median 3Y
34.5
Median 5Y
29.1
Industry
21.7
Forward
16.2
More Details
36.7
P/OCF
P/OCF
Price to OCF
36.7
vs History
3
vs Industry
36
Median 3Y
13.7
Median 5Y
13.3
Industry
16.6
More Details
37.3
P/FCFE
P/FCFE
Price to FCFE
37.3
vs History
3
vs Industry
29
Median 3Y
10.3
Median 5Y
10.4
Industry
22.5
More Details
2.5
P/B
P/B
Price to Book Value
2.5
vs History
4
vs Industry
42
Median 3Y
1.9
Median 5Y
1.9
Industry
2.3
More Details
3.5
EV/S
EV/S
Enterprise Value to Sales
3.5
vs History
3
vs Industry
49
Median 3Y
2.4
Median 5Y
2.6
Industry
2.9
Forward
3.3
More Details
3.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.8
vs History
6
vs Industry
66
Median 3Y
2.8
Median 5Y
2.9
Industry
5.5
More Details
18.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
18.6
vs History
11
vs Industry
37
Median 3Y
14.2
Median 5Y
11.5
Industry
13.1
Forward
18.1
More Details
56.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
56.8
vs History
19
vs Industry
28
Median 3Y
43.5
Median 5Y
24.2
Industry
16.6
Forward
16.5
More Details
32.8
EV/OCF
EV/OCF
Enterprise Value to OCF
32.8
vs History
3
vs Industry
43
Median 3Y
12.7
Median 5Y
12.7
Industry
15.8
More Details
33.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
33.3
vs History
3
vs Industry
34
Median 3Y
12.7
Median 5Y
12.8
Industry
19.1
More Details
2.3
EV/IC
EV/IC
Enterprise Value to IC
2.3
vs History
4
vs Industry
43
Median 3Y
1.5
Median 5Y
1.4
Industry
1.9
More Details

Multiples Across Competitors

SUPN Competitors Multiples
Supernus Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
2.6B USD 3.9 -137.9 18.6 56.8
US
Eli Lilly and Co
NYSE:LLY
939.8B USD 15.8 51 34.3 36.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
497B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
257.7B CHF 4.2 27.3 11.7 13.6
UK
AstraZeneca PLC
LSE:AZN
211.6B GBP 4.9 30.1 109 159.5
CH
Novartis AG
SIX:NOVN
203.1B CHF 4.5 17.6 11.2 14.5
US
Merck & Co Inc
NYSE:MRK
242.8B USD 3.8 12.8 9.1 10.8
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.5 9.3 10.8
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
146.6B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
US
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Average P/E: 23.4
Negative Multiple: -137.9
55%
N/A
US
Eli Lilly and Co
NYSE:LLY
51
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.3
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.1
38%
0.8
CH
Novartis AG
SIX:NOVN
17.6
17%
1
US
Merck & Co Inc
NYSE:MRK
12.8
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.5
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Average EV/EBITDA: 399.5
18.6
24%
0.8
US
Eli Lilly and Co
NYSE:LLY
34.3
33%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
109
10%
10.9
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.1
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
2%
4.7
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Average EV/EBIT: 1 712.9
56.8
53%
1.1
US
Eli Lilly and Co
NYSE:LLY
36.8
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.6
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
159.5
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.8
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3

See Also

Summary
SUPN intrinsic value, competitors valuation, and company profile.
DCF Valuation
SUPN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SUPN stock valuation using valuation multiples.
Wall Street Estimates
SUPN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SUPN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 302,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.